scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1010922902 |
P356 | DOI | 10.1007/S11523-013-0295-4 |
P698 | PubMed publication ID | 24114566 |
P2093 | author name string | Alaaeldin Shablak | |
Andrew Conn | |||
P2860 | cites work | Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review | Q21198850 |
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. | Q27824867 | ||
Global cancer statistics, 2002 | Q27860562 | ||
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
Management and preparedness for infusion and hypersensitivity reactions | Q30229857 | ||
Cancer statistics, 2000. | Q33895772 | ||
Metastatic colorectal cancer | Q34677913 | ||
A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer | Q35857638 | ||
Interstitial lung disease in lung cancer: separating disease progression from treatment effects. | Q36029824 | ||
Pulmonary toxicity from novel antineoplastic agents | Q36314452 | ||
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy | Q36610301 | ||
A rare but severe pulmonary side effect of cetuximab in two patients. | Q38030496 | ||
Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. | Q38071119 | ||
Cetuximab-associated pulmonary toxicity | Q43279298 | ||
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets | Q44535930 | ||
Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib | Q44936060 | ||
Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. | Q45997056 | ||
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma | Q46816802 | ||
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer | Q46892017 | ||
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group | Q56562473 | ||
P433 | issue | 2 | |
P921 | main subject | cetuximab | Q420296 |
interstitial lung disease | Q1153419 | ||
P304 | page(s) | 177-180 | |
P577 | publication date | 2013-10-10 | |
P1433 | published in | Targeted oncology | Q25378200 |
P1476 | title | A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment | |
P478 | volume | 9 |
Q40812370 | Adverse events of monoclonal antibodies used for cancer therapy |
Q90914261 | Cetuximab-associated pulmonary toxicity in concurrent chemoradiation for the treatment of a squamous cell carcinoma of the head and neck |
Q47672858 | Interstitial lung disease secondary to Cetuximab in bladder cancer: an Oncologist's perspective |
Search more.